Ovarian cancer has high mortality due to late diagnosis and limited therapeutic options. This study encapsulates paclitaxel (PTX) and sorafenib (SRF) into mPEG-b-PCL micelles to enhance efficacy while reducing toxicity. Micelles were optimized for drug loading, encapsulation efficiency, particle size, and stability. The selected formulation, with a PTX:SRF molar ratio of 1:2.3, showed synergistic cytotoxicity against ovarian cancer cell lines. In vitro drug release studies demonstrated a sustained release profile, with PTX and SRF being released more gradually compared to their free drug counterparts. In vivo pharmacokinetic analysis indicated improved bioavailability of PTX/SRF micelles over conventional formulations. In vivo toxicity studies showed no significant adverse effects. The anticancer efficacy of PTX/SRF micelles was superior to monotherapy, achieving a tumor growth inhibition rate of 90.44% in xenograft models. These findings suggest that PTX/SRF-loaded micelles represent a promising strategy for enhancing ovarian cancer treatment by improving drug solubility, stability, and therapeutic efficacy.